Group 1 - PMV Pharmaceuticals, Inc. (PMVP) shares have declined by 10.8% over the past week, but a hammer chart pattern suggests potential support and a trend reversal [1] - The hammer pattern indicates a possible exhaustion of selling pressure, with Wall Street analysts showing rising optimism about PMVP's future earnings [1] - The hammer chart pattern is characterized by a small candle body and a long lower wick, signaling a potential trend reversal when formed at the bottom of a downtrend [1] Group 2 - Recent upward revisions in earnings estimates for PMVP are considered a bullish indicator, correlating strongly with near-term stock price movements [2] - The consensus EPS estimate for the current year has increased by 5.7% over the last 30 days, indicating analysts' agreement on improved earnings potential [2] - PMVP holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [2]

Core Insights - Foundation Medicine and PMV Pharmaceuticals have partnered to develop FoundationOne®CDx as a companion diagnostic for PMV Pharma's investigational therapy rezatapopt, targeting patients with locally advanced or metastatic solid tumors having a TP53 Y220C mutation [1][4]. Company Overview - Foundation Medicine is a pioneer in molecular profiling for cancer, focusing on improving clinical care and research through collaborations across the cancer community [6]. - PMV Pharma specializes in precision oncology, developing small molecule therapies targeting p53 mutations, which are prevalent in approximately 50% of all cancers [9]. Product Details - FoundationOne®CDx is a next-generation sequencing-based diagnostic tool that detects genomic alterations in 324 genes, intended to guide personalized treatment decisions [7]. - Rezatapopt (PC14586) is a first-in-class small molecule designed to reactivate p53 function in patients with the TP53 Y220C mutation, which is thermally unstable and unable to effectively interact with DNA [2][8]. Clinical Development - The FDA has granted Fast Track designation to rezatapopt for treating patients with locally advanced or metastatic solid tumors with a TP53 Y220C mutation, and it is currently undergoing the registrational, tumor-agnostic PYNNACLE Phase 2 clinical trial [3][8].

Financial Performance - For the three months ended March 31, 2024, the company incurred a net loss of $15.3 million, compared to a net loss of $19.1 million for the same period in 2023, representing a decrease of $3.9 million[108]. - The accumulated deficit as of March 31, 2024, was $325.3 million, indicating ongoing financial challenges[114]. - The company incurred an accumulated deficit of $325.3 million through March 31, 2024, and expects to incur substantial additional losses as it expands research and development activities[120]. - Cash operating expenditures for the three months ended March 31, 2024, were $16.2 million, compared to $15.0 million for the same period in 2023, reflecting an increase of 8%[120]. - The company reported a net cash used in operating activities of $16.2 million for the three months ended March 31, 2024, primarily due to a net loss of $15.3 million[123]. Research and Development - Research and development expenses for the three months ended March 31, 2024, were $13.2 million, down from $15.1 million in the same period of 2023, a decrease of $1.9 million[109]. - The company initiated a Phase 1/2 clinical trial for its lead product candidate, PC14586, in October 2020, and has advanced to the pivotal Phase 2 trial in early 2024[95]. - The company plans to continue using third-party service providers for clinical development and manufacturing, as it currently lacks a sales force[99]. Cash and Financial Position - As of March 31, 2024, the company had cash and cash equivalents of $47.7 million, an increase of $9.9 million from $37.7 million as of December 31, 2023[113]. - Total financial assets decreased to $213.1 million as of March 31, 2024, from $228.6 million as of December 31, 2023, a decrease of $15.5 million[113]. - The company has cash, cash equivalents, and marketable securities totaling $213.1 million as of March 31, 2024, with restricted cash of $0.8 million[136]. - The company generated a net cash inflow of $26.2 million from investing activities during the three months ended March 31, 2024, primarily from maturities of marketable securities[125]. Future Outlook and Financing - The company anticipates that its cash resources will be sufficient to fund operations until the end of 2026, based on current research and development plans[120]. - The company expects to fund operations and capital needs through equity and/or debt financing until substantial revenue from product sales is generated[121]. - The company has a shelf registration statement with the SEC for offering up to $200 million in various securities and $150 million in common stock under its ATM Program, with approximately $113.8 million remaining for future issuances as of March 31, 2024[115]. - The company did not sell any shares under the ATM Program during the three months ended March 31, 2024[115]. Cost Management and Restructuring - General and administrative expenses decreased to $5.0 million for the three months ended March 31, 2024, from $6.4 million in the same period of 2023, a reduction of $1.4 million[110]. - A restructuring plan was announced on January 18, 2024, involving a workforce reduction of approximately 30%, expected to be completed by the end of Q3 2024[119]. - Interest income, net increased to $3.0 million for the three months ended March 31, 2024, compared to $2.4 million for the same period in 2023, an increase of $0.6 million[111]. - The company has not generated any revenue from product sales and does not expect to do so in the foreseeable future[101].

Exhibit 99.1 PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights • First patient dosed in Phase 2 portion of the PYNNACLE trial which will assess rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors • Phase 1 data of rezatapopt in advanced ovarian cancer featured in late-breaking oral presentation at 2024 SGO Annual Meeting on Women's Cancer • Cash, cash equivalents, and marketable securities of $213.1 million as of March 31, 20 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM ! 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39539 PMV PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) Delaware 46-3218129 (State or other jurisdic ...

Financial Performance - PMV Pharmaceuticals reported a net loss of $68.96 million for the year ended December 31, 2023, compared to a net loss of $73.32 million for the previous year, representing a decrease of approximately 6%[11] - Total operating expenses for the year were $80.13 million, compared to $77.04 million in 2022, marking an increase of approximately 4%[11] - Research and development expenses increased to $55.89 million in 2023 from $51.99 million in 2022, reflecting a rise of about 7% due to increased headcount and clinical expenses[11] - The company had cash, cash equivalents, and marketable securities totaling $228.6 million as of December 31, 2023, down from $243.5 million at the end of 2022[11] Clinical Development - The overall response rate in the Phase 1 PYNNACLE trial for rezatapopt was confirmed at 38%, with a median duration of response of seven months in the intended Phase 2 population[5] - The registrational, tumor-agnostic Phase 2 clinical trial of rezatapopt is on track to initiate in Q1 2024[5] - The company concluded a successful End-of-Phase 1 meeting with the FDA, aligning on the recommended Phase 2 dose and key elements of the Phase 2 registrational portion of the PYNNACLE study[11] - PMV Pharmaceuticals initiated enrollment in the combination arm of the PYNNACLE study with rezatapopt and KEYTRUDA®[11] Strategic Initiatives - PMV Pharmaceuticals expects cost savings from a workforce reduction initiated in January 2024 to extend its cash runway to the end of 2026[5] - The company appointed Charles Baum, M.D., Ph.D., as senior clinical advisor, enhancing its clinical development team[6]

Financial Performance - The net loss for the three months ended September 30, 2023, was $16.6 million, a decrease of $1.6 million compared to a net loss of $18.2 million for the same period in 2022[101]. - The company incurred a net loss of $53.2 million for the nine months ended September 30, 2023, compared to a net loss of $54.0 million for the same period in 2022, reflecting a decrease of $0.8 million[106]. - The accumulated deficit reached $294.2 million as of September 30, 2023, with cash operating expenditures of $43.6 million for the nine months ended September 30, 2023, compared to $48.4 million in 2022[117]. Research and Development Expenses - Research and development expenses for the three months ended September 30, 2023, were $13.6 million, a slight decrease of $0.1 million from $13.7 million in the same period in 2022[102]. - Research and development expenses for the nine months ended September 30, 2023, totaled $42.5 million, an increase of $5.5 million from $37.0 million in the same period in 2022[107]. - The company expects significant increases in operating expenses as it advances product candidates through clinical development and seeks regulatory approval[90]. Cash and Financial Assets - As of September 30, 2023, total financial assets were $238.1 million, a decrease of $5.4 million from $243.5 million as of December 31, 2022[111]. - The company expects its cash, cash equivalents, and marketable securities as of September 30, 2023, to be sufficient to fund operations at least through 2025[117]. - As of September 30, 2023, the company had cash, cash equivalents, and marketable securities totaling $238.1 million, with restricted cash of $0.8 million[139]. Interest Income - Interest income, net for the three months ended September 30, 2023, was $3.0 million, an increase of $1.9 million compared to $1.1 million for the same period in 2022, driven by higher interest rates[105]. - Interest income, net rose to $8.0 million for the nine months ended September 30, 2023, an increase of $6.2 million compared to the same period in 2022, driven by higher interest rates[109]. Operating Activities - Cash used in operating activities was $43.6 million for the nine months ended September 30, 2023, down from $48.4 million in the same period of 2022[120]. - Total operating expenses for the nine months ended September 30, 2023, were $61.2 million, an increase of $5.4 million compared to $55.9 million for the same period in 2022[106]. Financing Activities - Financing activities generated $35.3 million in cash during the nine months ended September 30, 2023, mainly from the issuance of common stock under the ATM Program[125]. - The company has approximately $113.8 million remaining in gross proceeds available for future issuances of common stock under the ATM Program as of September 30, 2023[113]. Market Risks - The company is exposed to market risks primarily related to interest rate risks in the ordinary course of business[138]. - The company is not currently exposed to significant market risk related to changes in foreign currency exchange rates, but future contracts with foreign vendors may introduce such risks[140]. Stock-Based Compensation - Stock-based compensation expense is recognized on a straight-line basis over the associated service period of the award[132]. - The company uses the Black-Scholes option pricing model to estimate the fair value of stock options on the date of grant[134]. - Expected volatility for stock options is derived from the average historical stock volatility over the expected term of the awards[135]. Other Information - The company has not generated any revenue from product sales to date and does not expect to do so in the foreseeable future[94]. - The company plans to continue using third-party service providers for clinical development and manufacturing, as it does not currently have a sales force[92]. - The company engages vendors, CROs, and CMOs for preclinical development activities and clinical trials[133]. - Recent accounting pronouncements are detailed in Note 2 of the unaudited condensed financial statements for the nine months ended September 30, 2023[137].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-3218129 (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39539 PMV PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 46-3218129 (State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM ! 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39539 PMV PHARMACEUTICALS, INC. (Exact name of Registrant as specified in its Charter) Delaware 46-3218129 (State or other jurisdic ...